BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ProMining Therapeutics Announced a Collaboration With Roche (RHHBY) for the Discovery of Small Molecule Therapeutics


12/17/2012 7:45:36 AM

JERUSALEM, December 17, 2012 /PRNewswire/ -- ProMining Therapeutics, Ltd. today announced a new collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) in the field of type 2 diabetes mellitus. Under the terms of the agreement, ProMining Therapeutics will use its CavitIIRx platform to develop small molecule therapeutics for treatment of type 2 diabetes mellitus and will receive research based funding. Further details of the agreement were not disclosed.

"We are pleased to have completed this agreement with Roche and are very excited by the prospect of jointly delivering novel therapeutic oral small molecules to patients suffering from type 2 diabetes mellitus. ProMining has developed novel technology for the discovery of small molecules interfering in protein-protein interactions that are clearly differentiated from conventional small molecule drugs. This partnership will enable ProMining to expand the exploitation of this technology by combining with the impressive global research and development capabilities and resources of Roche," says Dr. Iris Alroy, ProMining Therapeutics CEO.

About ProMining Therapeutics

ProMining Therapeutics, Ltd., based in Israel is a Van Leer Technology Ventures Jerusalem and Pontifax portfolio company established in 2011 by Dr. Silvia Noiman, Dr. Iris Alroy and Dr. Arnon Aharon and operating within the Van Leer incubator. The company is a biopharmaceutical research and development company engaged in the discovery and development of novel oral, small-molecule drugs for a variety of indications including: cancer, inflammation, chronic pain, cardiovascular and viral diseases.

The Company has developed CavitIIRx, a proprietary drug discovery and development platform, focused on SH3 domain-mediated protein-protein interactions, known to play a major role in numerous disease mechanisms. ProMining's approach includes integration of state-of-the-art computational analysis tools and novel biological assays directed towards identification of small molecules blocking SH3-partner interaction. These tools are applied for a fast discovery and development of SH3-partner inhibitors of different targets, thereby creating a substantial pipeline.

Within a year from its incorporation ProMining was able to identify protein-protein interfering small molecules for its oncology project. The oncology project targets the ArgBP2-PAK1 SH3 domain mediated interaction. ArgBP2 coordinates PI3K signaling of the PI3K/Akt/Bcl2 pathway, which plays a detrimental role in many cancers.

Contact:

Iris Alroy, Ph.D.

CEO

E-mail: irisalroy@prominingtherapeutics.com

Phone: +972-52-3961013



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES